Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Recurrent chromosomal rearrangements have not been well characterized in common carcinomas. We used a bioinformatics approach to discover candidate oncogenic chromosomal aberrations on the basis of outlier gene expression. Two ETS transcription factors, ERG and ETV1 , were identified as outliers in prostate cancer. We identified recurrent gene fusions of the 5′ untranslated region of TMPRSS2 to ERG or ETV1 in prostate cancer tissues with outlier expression. By using fluorescence in situ hybridization, we demonstrated that 23 of 29 prostate cancer samples harbor rearrangements in ERG or ETV1 . Cell line experiments suggest that the androgen-responsive promoter elements of TMPRSS2 mediate the overexpression of ETS family members in prostate cancer. These results have implications in the development of carcinomas and the molecular diagnosis and treatment of prostate cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The high expression levels of ERG and PEA3 subfamily members in a subset of prostate tumors led to the discovery of common chromosomal rearrangements associated with this human cancer (36).”
From Genomic and biochemical insights into the specificity of ETS transcription factors (2011) · cites this paper as [36]
In the citing paper
“Chromosomal rearrangements that result in the overexpression of members of the PEA3 subfamily (ETV1, ETV4, or ETV5) are found less frequently (36, 170, 171).”
From Genomic and biochemical insights into the specificity of ETS transcription factors (2011) · cites this paper as [36]
In the citing paper
“Rearrangements of ETS loci are a hallmark of prostate cancer with ~50% of tumors showing alterations at an ETS gene locus (36).”
From Genomic and biochemical insights into the specificity of ETS transcription factors (2011) · cites this paper as [36]
Citations
Cites
ROWLEY, J. D. (1973) · Nature · doi:10.1038/243290a0 · Cited by 4,291
Jemal, A., Murray, T., Ward, E., Samuels, A., Tiwari, R. C., Ghafoor, A., Feuer, E. J., & Thun, M. J. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.1.10 · Cited by 4,186
ONCOMINE: A Cancer Microarray Database and Integrated Data-Mining Platform
Rhodes, D. R., Yu, J., Shanker, K., Deshpande, N., Varambally, R., Ghosh, D., Barrette, T., Pander, A., & Chinnaiyan, A. M. (2004) · Neoplasia · doi:10.1016/s1476-5586(04)80047-2 · Cited by 3,612
Self-citationA census of human cancer genes
Futreal, P. A., Coin, L., Marshall, M., Down, T., Hubbard, T., Wooster, R., Rahman, N., & Stratton, M. R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1299 · Cited by 3,184
Sotiriou, C., Neo, S.-Y., McShane, L. M., Korn, E. L., Long, P. M., Jazaeri, A., Martiat, P., Fox, S. B., Harris, A. L., & Liu, E. T. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1732912100 · Cited by 1,993
Delineation of prognostic biomarkers in prostate cancer
Dhanasekaran, S. M., Barrette, T. R., Ghosh, D., Shah, R., Varambally, S., Kurachi, K., Pienta, K. J., Rubin, M. A., & Chinnaiyan, A. M. (2001) · Nature · doi:10.1038/35090585 · Cited by 1,673
Self-citationChromosomal translocations in human cancer
Rabbitts, T. H. (1994) · Nature · doi:10.1038/372143a0 · Cited by 1,503
Tian, E., Zhan, F., Walker, R., Rasmussen, E., Ma, Y., Barlogie, B., & Shaughnessy, J. D. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030847 · Cited by 1,503
A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia
Klein, A. D., Kessel, A. G. V., Grosveld, G., Bartram, C. R., Hagemeijer, A., Bootsma, D., Spurr, N. K., Heisterkamp, N., Groffen, J., & Stephenson, J. R. (1982) · Nature · doi:10.1038/300765a0 · Cited by 1,378
Prognostically Useful Gene-Expression Profiles in Acute Myeloid Leukemia
Valk, P. J. M., Verhaak, R. G. W., Beijen, M. A., Erpelinck, C. A. J., van Doorn-Khosrovani, S. B. V. W., Boer, J. M., Beverloo, H. B., Moorhouse, M. J., van der Spek, P. J., Löwenberg, B., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040465 · Cited by 1,370
Research works printed but not linked: 5
- I. S. Jeon et al., Oncogene10, 1229 (1995).
- B. Lin et al., Cancer Res.59, 4180 (1999).
- D. E. Afar et al., Cancer Res.61, 1686 (2001).
- S. M. Dhanasekaran et al., FASEB J.19, 243 (2005).
- J. B. Welsh et al., Cancer Res.61, 5974 (2001).
Cited by
Items 1,001–1,014 of 1,014
Current insights into the role of Fli-1 in hematopoiesis and malignant transformation
Ben-David, Y., Gajendran, B., Sample, K. M., & Zacksenhaus, E. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04160-1 · Cited by 54
Poly‐gene fusion transcripts and chromothripsis in prostate cancer
Wu, C., Wyatt, A. W., McPherson, A., Lin, D., McConeghy, B. J., Mo, F., Shukin, R., Lapuk, A. V., M. Jones, S. J., Zhao, Y., et al. (2012) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.21999 · Cited by 51
“In prostate cancer, multigenic events leading to the creation of key fusion genes which drive disease, such as TMPRSS2-ERG have been observed (Tomlins et al., 2005; Berger et al., 2011).”
BackgroundWasmuth, E. V., Hoover, E. A., Antar, A., Klinge, S., Chen, Y., & Sawyers, C. L. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1922159117 · Cited by 50
Barfeld, S. J., East, P., Zuber, V., & Mills, I. G. (2014) · BMC Medical Genomics · doi:10.1186/s12920-014-0074-9 · Cited by 47
Copy number alterations unmasked as enhancer hijackers
Beroukhim, R., Zhang, X., & Meyerson, M. (2017) · Nature Genetics · doi:10.1038/ng.3754 · Cited by 46
Nervous system regulation of the cancer genome
Cole, S. W. (2013) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2012.11.008 · Cited by 41
Roos-Weil, D., Decaudin, C., Armand, M., Della-Valle, V., Diop, M. K., Ghamlouch, H., Ropars, V., Hérate, C., Lara, D., Durot, E., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0873 · Cited by 38
Agoulnik, I. U., Bingman, W. E., Nakka, M., Li, W., Wang, Q., Liu, X. S., Brown, M., & Nancy L., N. L. (2008) · Molecular Endocrinology · doi:10.1210/me.2007-0481 · Cited by 36
Qi, F., Qin, W., & Zang, Y. (2019) · Oncology Letters · doi:10.3892/ol.2019.9884 · Cited by 32
Inherited determinants of early recurrent somatic mutations in prostate cancer
Romanel, A., Garritano, S., Stringa, B., Blattner, M., Dalfovo, D., Chakravarty, D., Soong, D., Cotter, K. A., Petris, G., Dhingra, P., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00046-0 · Cited by 29
Self-citationDing, D., Blee, A. M., Zhang, J., Pan, Y., Becker, N. A., Maher, L. J., Jimenez, R., Wang, L., & Huang, H. (2023) · Nature Communications · doi:10.1038/s41467-023-40352-4 · Cited by 27
Rapid interrogation of cancer cell of origin through CRISPR editing
Feng, W., Cao, Z., Lim, P. X., Zhao, H., Luo, H., Mao, N., Lee, Y. S., Rivera, A. A., Choi, D., Wu, C., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2110344118 · Cited by 25
“1-Mb intrachromosomal deletion that results in aberrant expression of the ETS family transcription factor ERG in human prostate cancer (23).”
BackgroundRye, M. B., Bertilsson, H., Andersen, M. K., Rise, K., Bathen, T. F., Drabløs, F., & Tessem, M.-B. (2018) · BMC Cancer · doi:10.1186/s12885-018-4373-y · Cited by 21
Destruction of DNA-binding proteins by programmable O’PROTAC: Oligonucleotide-based PROTAC
Shao, J., Yan, Y., Ding, D., Wang, D., He, Y., Pan, Y., Yan, W., Kharbanda, A., Li, H.-Y., & Huang, H. (2021) · doi:10.1101/2021.03.08.434493 · Cited by 2
Metadata
- Authors
- Tomlins, S. A., Rhodes, D. R., Perner, S., Dhanasekaran, S. M., Mehra, R., Sun, X.-W., Varambally, S., Cao, X., Tchinda, J., Kuefer, R., Lee, C., Montie, J. E., Shah, R. B., Pienta, K. J., Rubin, M. A., & Chinnaiyan, A. M.
- Affiliations
- University of Michigan (US)
- Department of Pathology, University of Michigan Medical School, 1301 Catherine Street, Ann Arbor, MI 48109–0602, USA.
- Corresponding author
- Chinnaiyan, Arul M.
- ORCID
- Venue
- Science
- Published
- 2005-10-28
- Volume
- 310
- Issue
- 5748
- Pages
- 644-648
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2121158863
- Cited by
- 3,846
- References
- 32
- Citations by year
- 2026: 77 · 2025: 99 · 2024: 82 · 2023: 108 · 2022: 137 · 2021: 163 · 2020: 187 · 2019: 172 · 2018: 178 · 2017: 218 · 2016: 209 · 2015: 244 · 2014: 271 · 2013: 309 · 2012: 279
- FWCI
- 114.43
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (R01AG021404, R01 AG 21404)
- National Cancer Institute (UO1 CA111275-01, P50-CA-69568, U01CA111275, R01CA097063, R01 CA97063, 5P30 CA 46592, P50CA069568, P30CA046592)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
- Keywords
- TMPRSS2-ERG fusion, prostate cancer, ETS transcription factors, chromosomal rearrangements, gene fusion, molecular diagnosis
- MeSH terms
- Transcriptional Regulator ERG, Androgens, DNA-Binding Proteins, Humans, Male, Membrane Proteins, Molecular Sequence Data, Neoplasm Proteins, Prostatic Neoplasms, Serine Endopeptidases, Transcription Factors, Translocation, Genetic, Gene Rearrangement, Oncogene Proteins, Fusion, Trans-Activators, Gene Expression Regulation, Neoplastic, Polymerase Chain Reaction, In Situ Hybridization, Fluorescence, Cell Line, Tumor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.